New book by Larry Connors Click here Improve your trading - See how
Spire Corp. (NASDAQ: SPIR | Quote | Chart | News | PowerRating) engages in the development, manufacture, and marketing of engineered products and services in the areas of PV solar, biomedical, and optoelectronics in the United States and internationally. The company offers specialized equipment for the production of terrestrial photovoltaic modules from solar cells. It also provides value-added surface treatments to manufacturers of orthopedic and other medical devices; develops and markets coated and uncoated hemodialysis catheters and related devices for the treatment of chronic kidney disease; and performs sponsored research programs into practical applications of advanced biomedical and biophotonic technologies. In addition, the company offers custom compound semiconductor foundry and fabrication services to customers involved in biomedical/biophotonic instruments, telecommunications, and defense applications. It also involves in compound semiconductor wafer growth, thin film and related device processing, and fabrication services. Further, Spire Corporation provides materials testing services, as well as offers services in support of sponsored research into practical applications of optoelectronic technologies. The company sells its products and services primarily through its independent sales representatives and distributors, as well as grants licenses to third parties to sell its products. Spire Corporation was founded in 1969 and is headquartered in Bedford, Massachusetts. With 8.33 million shares outstanding and 753,200 shares declared short as of July 2008, there is no longer a failure to deliver in shares of SPIR. According to quarterly data provided by the SEC, there were still 22,278 shares of SPIR that were failing-to-deliver as of September 28, 2007.
Synovis Life Technologies Inc. (NASDAQ: SYNO | Quote | Chart | News | PowerRating) a medical device company, engages in the development, manufacture, marketing, and sale of products for the surgical treatment of disease. Its products include implantable biomaterial products and devices for microsurgery and surgical tools, which are used to reduce risk and/or facilitate critical surgeries. The company also offers biomaterial products, such as Peri-Strips that are biomaterial stapling buttress used as reinforcement at the surgical staple line; Tissue-Guard, which is used to repair and replace damaged tissue in cardiac, vascular, thoracic, and neurologic procedures; and Veritas for use in surgery to repair and replace soft tissue. In addition, it offers devices for microsurgery, including Microvascular Anastomotic Coupler, which enables microsurgeons in various surgical specialties to perform anastomotic microsurgical procedures; and Neurotube, a device designed to assist in the reconnection of severed nerves. The company was incorporated in 1985. It was formerly known as Bio-Vascular, Inc. and changed its name to Synovis Life Technologies, Inc. in 2002. Synovis Life Technologies is headquartered in St. Paul, Minnesota. With 12.46 million shares outstanding and 1 million shares declared short as of July 2008, there is no longer a failure to deliver in shares of SYNO.
Telik Inc. (NASDAQ: TELK | Quote | Chart | News | PowerRating) a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of cancer and inflammatory diseases. Its products include TELCYTA, a small molecule tumor-activated cancer product candidate designed to be activated in cancer cells, which has completed three randomized Phase 3 registration trials in platinum refractory or resistant ovarian cancer and in platinum resistant non-small cell lung cancer; TELINTRA, a small molecule bone marrow stimulant that has completed Phase 2 clinical trial for the treatment of blood disorders associated with low blood cell levels, such as neutropenia or anemia; and TLK58747, which is in Pre-IND stage that causes apoptosis and G2/M cell cycle arrest in human cancer cell. The company's products also include Aurora kinase, Vascular Endothelial Growth Factor Receptor 2, Polo-like kinase 1, Proteasome, and DNA methyltransferase inhibitor for the treatment of cancer; and MCP-1 antagonist (C243) that is in preclinical and safety assessment stage for the treatment of multiple sclerosis, rheumatoid arthritis, atherosclerosis, and other inflammatory and autoimmune diseases. It has a collaborative agreement with Sanwa Kagaku Kenkyusho Co., Ltd. to identify compounds that are active against biological targets; a license agreement with SRI International to conduct preclinical studies of C243; and research and license agreements with the The University of Arizona and Mount Sinai School of Medicine for the identification of small molecule compounds active against cancer related targets. Telik, Inc. was founded in 1988. It was formerly known as Terrapin Diagnostics, Inc. and changed its name to Telik, Inc. in 1998. The company is based in Palo Alto, California. With 53.16 million shares outstanding and 4.06 million shares declared short as of July 2008, there is no longer a failure to deliver in shares of TELK. According to quarterly data provided by the SEC, there were still 465,204 shares of TELK that were failing-to-deliver as of September 28, 2007.
TGC Industries Inc. (NASDAQ: TGE | Quote | Chart | News | PowerRating) provides seismic data acquisition services primarily to onshore oil and natural gas exploration and development companies in the continental United States. The company conducts 3-D surveys to acquire geophysical data; and owns a data bank that contains gravity data and magnetic data, from oil and natural gas producing areas located in the United States. As of December 31, 2007, it operated eight land-based seismic data acquisition crews, which supplied seismic data to companies engaged in the domestic exploration and development of oil and natural gas on land and in land-to-water transition areas. The company was founded in 1967 and is headquartered in Plano, Texas. With 16.56 million shares outstanding and 113,300 shares declared short as of July 2008, there is no longer a failure to deliver in shares of TGE.
Tumbleweed Communications Corp. (NASDAQ: TMWD | Quote | Chart | News | PowerRating) provides managed file transfer, email security, and identity validation products to enterprise and government customers worldwide. Its solutions enable organizations to safely and confidently conduct business over the Internet, protecting data in motion and at rest with intuitive, pragmatic solutions that promote collaboration, prevent data loss, and reduce the cost of doing business. The company offers SecureTransport, an enterprise-class managed file transfer solution that enables customers to securely manage the exchange of large files and transactions without having to change internal infrastructure; Secure Messenger, a policy-based email encryption product, which enables deep-content inspection of incoming and outgoing mail, and dynamic application of user-defined encryption and routing preferences; MailGate, a comprehensive email security product that provides inbound and outbound protection with protection against virus outbreaks, spam, and denial of service attacks, eliminating illegitimate email traffic before it can penetrate corporate firewalls; and Validation Authority, a product for determining the validity of digital certificates. The company sells its products directly and through channel partners to enterprises in the financial services, healthcare, and government markets. The company was founded in 1993 and is based in Redwood City, California. With 51.18 million shares outstanding and 186,000 shares declared short as of July 2008, there is no longer a failure to deliver in shares of TMWD. According to quarterly data provided by the SEC, there were still 31,054 shares of TMWD that were failing-to-deliver as of August 17, 2007.
Valence Technology Inc. (NASDAQ: VLNC | Quote | Chart | News | PowerRating) together with its subsidiaries, engages in the development, manufacture, and sale of energy power storage systems. Its products include N-Charge lithium phosphate energy storage systems; Epoch lithium phosphate energy storage systems for motive applications, such as hybrid and electric vehicles, scooters, and wheelchairs; and U-Charge lithium phosphate energy storage systems for use in hybrid and full electric vehicles, wheelchairs, scooters, robotics, marine, remote power, military, back-up, and other devices. The company sells its products through national and regional retailers, computer manufacturers, and national resellers in the United States and internationally. Valence Technology was founded in 1989 and is headquartered in Austin, Texas. With 118.12 million shares outstanding and 14.3 million shares declared short as of July 2008, there is no longer a failure to deliver in shares of VLNC. According to quarterly data provided by the SEC, there were still 80,507 shares of VLNC that were failing-to-deliver as of September 28, 2007.
About BUYINS.NET
WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.
BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 2,100,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.
The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.
All material herein was prepared by BUYINS.NET, based upon information believed to be reliable. The information contained herein is not guaranteed by BUYINS.NET to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. BUYINS.NET is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. BUYINS.NET may receive compensation in cash or shares from independent third parties or from the companies mentioned.
BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. Market commentary provided by Thomas Ronk.
BUYINS.NET will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.
You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BUYINS.NET undertakes no obligation to update such statements.
CONTACT: Thomas Ronk, CEO, BUYINS.NET Tel: +1 800 715 9999 e-mail: Tom@buyins.net WWW: http://www.buyins.net
M2 Communications Ltd disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.
More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index
About TradingMarkets | Contact | Advertise | Careers | Link to Us | Site Map | Help | Terms & Conditions | Privacy Policy | Return Policy | Testimonials | Feedback
